Non-Invasive Ophthalmic Liposomes for Nucleic Acid Delivery to Posterior Segment of Eye

  • Takashima Yuuki
    Pharmaceutical Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Tsuchiya Tomohiro
    Pharmaceutical Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Igarashi Yuko
    Pharmaceutical Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Kanazawa Takanori
    Pharmaceutical Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Okada Hiroaki
    Pharmaceutical Technology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • Urtti Arto
    Centre for Drug Research, Faculty of Pharmacy, University of Helsinki

Bibliographic Information

Other Title
  • 後眼部指向型核酸封入リポソーム点眼剤の設計
  • ゴガンブ シコウガタ カクサン フウニュウ リポソーム テンガンザイ ノ セッケイ

Search this article

Description

  Nucleic acids like siRNA and pDNA are remarkable for treatment of ophthalmic diseases in posterior segment of eye such as age-related macular degeneration (AMD). However, hydrophilic and high molecule compounds are restricted in intraocular distribution through anterior segment of the eye. In addition, the ocular tissue has a blood-retinal barrier which restricts drug delivery thorough systemic administration. Therefore the invasive intravitreal injection has been generally applied for treatment of retinal diseases. The objective in this study is to prepare nucleic acid-loaded liposomes for effective gene delivery to posterior segment of eye by non-invasive ophthalmic administration such as eye-drops. The pDNA/PEI-complex loaded liposomes were prepared using detergent removal method. The obtained liposomes were lyophilized with optimal amount of a cryoprotectant to avoid changes in physical properties and, followed by adjustment of an appropriate volume and osmotic pressure as ophthalmic solution. The liposomes show high pDNA encapsulation efficiency and good cellular uptake ability in human retinal pigment epithelial cells (ARPE-19 cells). We further demonstrate that the modification of ligand which binds to specific receptor on the RPE cells to the liposomes may improve gene delivery efficacy to the posterior segment of eye by non-invasive ocular instillation.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 132 (12), 1365-1370, 2012-12-01

    The Pharmaceutical Society of Japan

Citations (1)*help

See more

References(11)*help

See more

Details 詳細情報について

Report a problem

Back to top